IBD & Intestinal Disorders
News
Biopsy not required to diagnose most cases of pediatric celiac disease
An updated guidance from the European Society of Pediatric Gastroenterology, Hepatology, and Nutrition could facilitate diagnosis and reduce...
Conference Coverage
Can diet, microbiome personalization reverse IBD increase?
AUSTIN, TEX. – Personalization of treatments with improved diet and microbial manipulations could reverse the rising incidence of inflammatory...
News
FDA strengthens warning regarding clozapine, serious bowel complication risk
Clozapine affects bowel function in a majority of patients, and constipation is a common adverse event associated with clozapine use.
News
FDA approves fidaxomicin for treatment of C. difficile–associated diarrhea in kids
Approval was based on results from SUNSHINE, a phase 3, multicenter, investigator-blind, randomized, parallel-group study in 142 pediatric...
Conference Coverage
Eluxadoline effective for IBS in loperamide nonresponders
SAN ANTONIO – Phase 4 trial shows eluxadoline improves a broad range of symptoms beyond stool problems.
Conference Coverage
Human milk oligosaccharides quell IBS symptoms
SAN ANTONIO – Restoring the altered gut microbiota in patients with IBS pays off in reduced abnormal stools, pain, and bloating.
Conference Coverage
Some with mild Crohn’s disease need no treatment
SAN ANTONIO – Know the risk factors for progression of mild Crohn’s disease.
News
Bile acid diarrhea guideline highlights data shortage
New clinical practice guidelines from the Canadian Association of Gastroenterology focus on the management of bile acid diarrhea.
News
FDA approves tenapanor for IBS with constipation
Improvements in number of complete spontaneous bowel movements and abdominal pain were seen as early as week 1 of the phase 3 trials.
News
Older IBD patients are most at risk of postdischarge VTE
Readmission for venous thromboembolism in patients with inflammatory bowel diseases most often occurs within 60 days of discharge.